Liposomal nanoparticles are the most commonly used drug nano-delivery platforms. However, recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric nanoparticles have the potential to enhance tumor growth and inhibit antitumor immunity in murine cancer models. We sought herein to identify the mechanisms and determine whether PLN-associated immunosuppression and tumor growth can be reversed using alendronate, an immune modulatory drug. By conducting in vivo and ex vivo experiments with the immunocompetent TC-1 murine tumor model, we found that macrophages were the primary cells that internalized PLN in the tumor microenvironment and that PLN-induced tumor growth was dependent on macrophages. Treatment with PLN increased immunosuppression as evidenced by increased expression of arginase-1 in CD11b + Gr1 + cells, diminished M1 functionality in macrophages, and globally suppressed T-cell cytokine production. Encapsulating alendronate in PLN reversed these effects on myeloid cells and shifted the profile of multi-cytokine producing T-cells towards an IFNγ + perforin + response, suggesting increased cytotoxic functionality. Importantly, we also found that PLN-encapsulated alendronate (PLN-alen), but not free alendronate, abrogated PLN-induced tumor growth and increased progression-free survival. In summary, we have identified a novel mechanism of PLN-induced tumor growth through macrophage polarization and immunosuppression that can be targeted and inactivated to improve the anticancer efficacy of PLN-delivered drugs. Importantly, we also determined that PLN-alen not only reversed protumoral effects of the PLN carrier, but also had moderate antitumor activity. Our findings strongly support the inclusion of immune-responsive tumor models and in-depth immune functional studies in the preclinical drug development paradigm for cancer nanomedicines, and the further development of chemo-immunotherapy strategies to co-deliver alendronate and chemotherapy for the treatment of cancer.
A B S T R A C T
Liposomal nanoparticles are the most commonly used drug nano-delivery platforms. However, recent reports show that certain pegylated liposomal nanoparticles (PLNs) and polymeric nanoparticles have the potential to enhance tumor growth and inhibit antitumor immunity in murine cancer models. We sought herein to identify the mechanisms and determine whether PLN-associated immunosuppression and tumor growth can be reversed using alendronate, an immune modulatory drug. By conducting in vivo and ex vivo experiments with the immunocompetent TC-1 murine tumor model, we found that macrophages were the primary cells that internalized PLN in the tumor microenvironment and that PLN-induced tumor growth was dependent on macrophages. Treatment with PLN increased immunosuppression as evidenced by increased expression of arginase-1 in CD11b + Gr1 + cells, diminished M1 functionality in macrophages, and globally suppressed T-cell cytokine production. Encapsulating alendronate in PLN reversed these effects on myeloid cells and shifted the profile of multi-cytokine producing T-cells towards an IFNγ + perforin + response, suggesting increased cytotoxic functionality. Importantly, we also found that PLN-encapsulated alendronate (PLN-alen), but not free alendronate, abrogated PLN-induced tumor growth and increased progression-free survival. In summary, we have identified a novel mechanism of PLN-induced tumor growth through macrophage polarization and immunosuppression that can be targeted and inactivated to improve the anticancer efficacy of PLN-delivered drugs. Importantly, we also determined that PLN-alen not only reversed protumoral effects of the PLN carrier, but also had moderate antitumor activity. Our findings strongly support the inclusion of immune-responsive tumor models and in-depth immune functional studies in the preclinical drug development paradigm for cancer nanomedicines, and the further development of chemo-immunotherapy strategies to co-deliver alendronate and chemotherapy for the treatment of cancer.
Introduction
Nanoparticle-based drugs are a heterogeneous class of pharmaceuticals, also referred as nanomedicines, characterized by the co-formulation of one or more active drug entities with a carrier system [26, 48] . The resulting nanomedicines are within the nanometer scale, usually in the range of 10 to 200 nm in diameter. Nanoparticles are used as drug carriers for cancer therapies since they have pharmacological advantages such as increased tumor drug delivery through the enhanced permeability and retention (EPR) effect, protection of the drug cargo from degradation, and in most cases improved tolerability of cytotoxic drugs [3, 20, 50] . There are now nine nanoparticle drugs approved for the treatment of cancer (Supplemental Table S1 ), and most utilize liposomal nanoparticles because the lipid components are considered biocompatible and safe materials and liposomes have been manufactured in bulk and met regulatory criteria. However, many liposomal drugs and other nanoparticle-based drug formulations have failed to meet regulatory criteria for approval or have shown only modest anticancer efficacy in phase 3 clinical studies [4, 23, 25, 38, 49, 52] . A recent meta-analysis of 14 randomized clinical trials that directly compared the anticancer efficacy of liposomal formulations of cytotoxic chemotherapy to their conventional "free" drug formulation found that liposome encapsulation of drugs did not improve objective response rates, progression-free survival, or overall survival in patients with solid tumors [52] . Currently the only liposomal drug to significantly prolong cancer patient survival in a head-tohead trial with the equivalent conventional formulation is CPX-351 (Vyxeos; liposomal daunarubicin and cytarabine). This was achieved via co-delivery of two cytotoxic drugs in patients with acute myelogenous leukemia [39] where the EPR effect would not be expected to play a role. This implies that there are critical knowledge gaps in the current understanding of the pharmacology of liposomal drugs in the treatment of cancer that need to be addressed in order to make major advances in the field.
Although the reasons for the lack of translation between preclinical anticancer efficacy and clinical findings are not fully understood, it is likely that the immune system is a key player since nanoparticles are known to activate or inhibit components of the immune system. The tumor microenvironment is infiltrated by a multitude of antitumor effector immune cells and immunosuppressive cells recruited by the tumor. Tumor evasion of CD8 + T-cell cytolytic activity is associated with disease progression [75] and there are several mechanisms by which the tumor evades CD8 + T-cell mediated destruction such as downregulation of MHC Class I and mutation of antigenic proteins [6] . While liposomes are unlikely to manipulate the mechanisms involved in immune-mediated recognition of tumors, there is evidence suggesting they contribute to the recruitment or induction of immunosuppressive cell types into the tumor microenvironment [13] . Myeloid-derived suppressor cells (MDSCs), that highly express arginase-1 and produce anti-inflammatory cytokines infiltrate tumors and secondary lymphoid organs in tumor-bearing mice and inhibit T-cell antitumor responses and enhance tumor angiogenesis leading to tumor progression [21, 44] . Beyond MDSCs, other myeloid cells such as tumor-associated macrophage (TAMs) also regulate antitumor immunity. While classically activated inflammatory macrophage, known as M1 macrophage, can inhibit tumor growth through inducible nitric oxide synthase (iNOS)-mediated production of reactive nitrogen species (RNS), many TAMs are instead polarized as alternatively activated anti-inflammatory M2 macrophage. M2 macrophages do not express iNOS but have elevated expression of arginase that prevents nitric oxide production, and secrete anti-inflammatory cytokines such as IL-10 and TGFβ. The clinical implications of interactions between nanomedicines and the immune system have been previously reviewed in detail [36] . Briefly, these interactions with the immune system can affect drug tolerability, immunogenicity, and pharmacokinetics in patients. However, their impact on tumors is only beginning to be elucidated. It was reported that polystyrene nanoparticles enhanced tumor growth in murine cancer models through mechanisms involving complement C5a receptors and MDSCs, suggesting that interactions between nanoparticles and the immune system can have protumoral effects [46] . In addition, we have previously reported that a poly-ethylene glycol (PEG)-coated (pegylated) liposomal nanoparticle (PLN) carrier, similar to that used in patients, significantly enhanced tumor growth in mice bearing TC-1 tumors, a mouse model of human papilloma virus (HPV)-induced cancer [56] . In these studies, PLNs were administered as weekly intravenous injections at clinically relevant lipid doses (four doses of 47 nmoles/g or two doses of 85 nmoles/g). Treatment with PLN was associated with suppression of antitumor immunity as indicated by decreased interferon-γ (IFNγ) production by tumor-associated macrophages (TAMs) and cytotoxic T-cells, diminished tumor infiltration of HPV E7-tumor antigen-specific T-cells, and decreased number of dendritic cells in tumor draining lymph nodes. These data suggest that PLN-induced immunosuppression and tumor enhancement may mitigate the benefits of carrier-mediated drug delivery ( Fig. 1 ) and could partially explain why there is often an insufficient improvement in the clinical efficacy of liposomal drugs over free drugs [23, 38, 45, 49] . The mechanisms underlying the observed PLN-associated tumor promotion are currently not known but it is likely that immunosuppressive cells such as TAMs are mediators since they have been implicated as players in both the pharmacology of liposome-mediated therapies [10, 37] and in cancer progression [21, 43] . In theory, the tumor promoting effects of the PLN may diminish the antitumor effects of the drug cargo. However, it is also possible that cytotoxic cargo may kill not only tumor cells but also immune cells responsible for the tumor promoting effects of the carrier, thus mitigating the PLN impact on cancer progression.
The imperative question that must be answered then is how the drug cargo alters the tumor-promoting and immune modulatory effects of the carrier. Nanoparticles are increasingly used as carriers for targeted therapies and immunotherapies that have significantly less direct cytotoxic effects on immune cells than traditional chemotherapy. In this scenario, the interactions between the carrier and the immune system can be of paramount importance to the overall anticancer efficacy of the carrier-mediated drug. The primary purpose of this study was to identify the subpopulation of immune cells which mediate the tumor promoting effects of particulate carrier systems, and to determine whether the tumor promoting and immunosuppressive effects of the carrier can be reversed with an immune modulatory and non-cytotoxic drug cargo. We chose PLN as the model carrier since we previously observed enhanced tumor growth with this nanoparticle [56] . We chose alendronate, an aminobisphosphonate, as the model drug cargo because PLN-encapsulated alendronate (PLN-alen) is not cytotoxic to leukocytes [51] and our formulation did not deplete tissue macrophages (Supplemental Fig. S1 ). Moreover, alendronate has been found to have antitumor activity through its effects on T-cells [55] which we theorized would mitigate the immunosuppressive effects of the PLN carrier.
Materials and methods

Cells
TC-1 tumorigenic cells were cultured under standard conditions similar to previously described methods [40] . TC-1 cells are derived from primary epithelial cells of C57BL/6 mice that have been cotransformed with HPV-16 E6 and E7 and c-Ha-ras oncogenes. TC-1 is an established tumor model utilized for the development of cancer immunotherapy since it is responsive to immune modulation and is characterized by immune cell infiltrates [32] .
Formulations
Placebo (i.e., no drug loaded within) PLN similar in size and composition to the Doxil® (pegylated liposomal doxorubicin; PLD) drug carrier, were synthesized using standard extrusion methods as previously described [19] . The PLNs were unilamellar and composed of hydrogenated phosphatidylcholine, cholesterol, and methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine at a molar ratio of 55:40:5, respectively, with an average diameter of 80 nm and poly dispersity index (PDI) ≤ 0.10 as determined by dynamic light scattering. Similar PLNs were also loaded with ammonium alendronate (PLN-alen) at the maximum loadable concentration, 4 to 5 mg/ml, depending on the batch. Unencapsulated alendronate was removed by dialysis along with anion exchange resin chromatography, as described previously [51, 59] . The PLN-alen particles were typically 70-90 nm in mean diameter with PDI approximately 0.05. The alendronate concentration was verified post synthesis and drug release profiles in buffer and plasma determined as previously detailed [59] . In buffer, PLN-alen is very stable with negligible leakage of alendronate for at least 1 year storage at 4°C. In plasma, it is also very stable for several hours incubation at 37°C. All formulations were endotoxin-free and sterile.
Animals and treatments
Six to twelve weeks old male and female wildtype C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME), macrophage FAS-induced apoptosis (MaFIA) transgenic mice on C57BL/6 background (Jackson Laboratories), and OT1 transgenic mice on C57BL/6 background (Jackson Laboratories) were housed and cared for at the Texas Tech University Health Sciences Center (TTUHSC) animal care facility (Abilene, Texas) according to the Institutional Animal Care and Use Committee guidelines and all procedures were conducted under an approved protocol. To evaluate the effect on tumors, 0.5 × 10 6 TC-1 tumorigenic cells were implanted subcutaneously on the hind flank and tumor volume was monitored at least twice weekly using digital calipers. Tumor volume was estimated using the formula: Volume = A * B 2 /2, where A = largest diameter and B = smaller diameter.
To identify the cell types which internalized intravenously administered PLN, wildtype mice (n = 8 total) bearing TC-1 implanted tumors were randomized to be treated with fluorescent nitrobenzoxadiazole (NBD)-labelled PLN or vehicle control. The mice were sacrificed 48 h later, tumors were resected and enzymatically processed to obtain single cell suspensions which were then stained with antibodies against CD45, CD11b, F4/80 and Gr-1, and liposome uptake by different cell populations was visualized using imaging flow cytometry (ImageStreamX, EMD Millipore) and quantified using conventional flow cytometry (BD LSR Fortessa) (details are in Supplemental materials).
MaFIA mice (n = 24 total) were used to determine the role of macrophages in PLN-induced tumor growth. In MaFIA mice, colony stimulating factor receptor 1 (Csf1r) drives expression of FK506 binding protein 1A (Fas), an inducible "suicide" gene. Since Csf1r is expressed in macrophages and not lymphocytes, this allows selective elimination of up to 90% of systemic macrophages after administration of the Fas receptor ligand, AP20187 (Clontech) [8] . Depletion of macrophages was achieved by intraperitoneal administration of AP20187 as described previously [8] . Mice were randomized to receive AP20187 or vehicle control (4% ethanol, 1% PEG, 1.7% Tween in water) and mice in each group were further randomized to receive PLN at 85 nmoles of phospholipids per gram body weight or equivalent volume of the vehicle (5% dextrose solution) administered via tail vein injections for two weekly doses.
To assess the impact of PLN and PLN-alen on immune functionality, wildtype mice (n = 12) were randomly allocated into treatment groups to receive PLN at 85 nmoles of phospholipids per gram body weight, PLN-alen at equivalent phospholipid concentration (alendronate at 7 μg/g), or equivalent volume of vehicle (5% dextrose solution) via tail vein injections. Animals were sacrificed 7 days later for collection of splenocytes since prior experiments indicated that this was the time when PLN-alen induced effects on splenocytes peaked. The alendronate dose is compatible with the maximum tolerated dose of PLN-alen determined in prior experiments (unpublished).
To determine the impact on tumor growth, mice (n = 28) were subcutaneously implanted with 0.5 × 10 6 TC-1 tumorigenic cells on the hind flank and randomized 72 h later to receive PLN, PLN-alen, PLN + free alendronate (at equivalent phospholipid and alendronate concentrations), or equivalent volume of vehicle control (5% dextrose solution) via tail vein injections as described above. Tumor size was measured twice weekly with digital calipers. To evaluate the acute changes in tumor immune cell infiltration, mice bearing TC-1 tumors (n = 24) were sacrificed 48 h after dosing with PLN, PLN-alen, or vehicle and tumor tissue collected for analysis since this is the time of peak PLN-alen accumulation in tumor tissue [59] .
Cell isolation and tissue processing
Spleens and tumors were excised and processed to obtain single cell suspensions as previously described [56] . Briefly, spleens were dissociated and passed through a 40 μm cell strainer, and red blood cells were lysed with ACK solution (K.D Medical, Columbia, Maryland). Tumors were minced then enzymatically digested and further purified using 30% Percoll density gradient. Single cell suspensions were counted and viability assessed using trypan blue exclusion assay (ViCell XR, Beckman Coulter Inc. California, USA). Cells were then aliquoted out for staining and flow cytometric analyses, or ex vivo functional studies as detailed below. In some experiments, tumor tissue was immediately stored in RNALater at − 20°C. RNA-stabilized tumor tissue was subsequently processed with the RNeasy RNA extraction kit (Qiagen) in order to obtain total RNA (500 ng) that was then converted to cDNA using the High Capacity Reverse Transcriptase Kit (Thermo Fisher/Applied Biosystems). The cDNA was analyzed by quantitative polymerase chain reaction (qPCR) using a StepOnePlus Real Time PCR System (Thermo Fisher) with primers specific for iNOS, TNFα, IFNγ, and expression was normalized to 18S rRNA.
Immunophenotyping
Two million cells from each sample were stained for CD45 and myeloid cell markers (CD11b, Gr1, F4/80, CD11c) or T-cell markers (TCR-β, CD8b, CD4). After surface staining, cells in the myeloid panel were fixed, permeabilized, and stained for expression of iNOS and arginase-1 (Arg1). Details of the staining panel are in Supplemental materials (Supplemental Tables S2 and S3 ). Samples were analyzed with a BDLSR Fortessa flow cytometer (BD Biosciences, San Jose, CA) and results analyzed using FlowJo software (Tree Star Inc., Ashland, Oregon, USA). One million events were acquired and single cells were gated using the forward scatter and side scatter parameters, followed by dead cell exclusion via a fixable viability dye (eBioscience, cat. 65-0866-14 Fig. S2 ).
Ex vivo functional studies
In some experiments, an aliquot of each single cell suspension was also used for evaluation of ex vivo T-cell cytokine production studies. Myeloid cells expressing CD11b were removed using a magnetic beadbased assay (Dynabeads FlowComp Flexi kit, ThermoFisher Scientific) according to the product instructions. The remaining splenocytes were stimulated in complete RPMI media with 10% FBS, with cell activation cocktail containing PMA:Ionomycin:Brefeldin A (0.08uM:1.3uM:5 μg/ ml) (Biolegend, San Diego, CA) at 37°C for 6 h in order to activate intracellular signaling cascades that mimic activation through T-cell receptor, then stained for intracellular cytokines (IFNγ, TNFα, IL-2) and perforin. Samples were analyzed similar to the method described above (staining panels are in Supplemental materials).
Statistical analysis
Statistical analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary, NC), and all data are expressed as mean + standard error of the mean (SEM), unless otherwise specified. For longitudinal observations of tumor growth, a two-factor (time vs. treatments) repeated measures model with interaction between time and the treatments was considered and tumor volume at endpoint were compared using the Holm-Tukey simultaneous multiple comparisons of the treatment effects in order to control the familywise (overall) Type I error rate. To compare two treatments based on small sample sizes, the exact Wilcoxon rank-sum test was used for each comparison since this method produces the most reliable analysis for small data sets. If data sets involving pairwise comparisons of more than two treatments were observed to be heteroscedastic, rank transformation was used to alleviate heteroscedasticity and then simultaneous pairwise comparisons of treatment effects were conducted based on the rank-transformed data for the one-way analysis of variance model [41, 42] . For analysis of progression-free survival, tumor-free survival was defined as a tumor volume < 100 mm 3 , and Kaplan-Meier survival curves were used to compare across treatment groups using the Log-Rank test. Tumor growth to > 100 mm 3 volume was considered a tumor progression
event. An adjusted P-value (the smallest familywise error rate at which the hypothesis can be rejected) of < 0.05 was considered statistically significant.
Results
Macrophages mediate protumoral effects of pegylated liposomes
It was recently reported that PLN significantly enhanced tumor growth in a murine model of cancer and this was associated with diminished T-cell functionality and tumor infiltration [56] , suggesting inhibition of antitumor immunity. We theorized that mechanisms of PLN-induced tumor growth involve immunosuppressive leukocytes such as tumor-associated macrophages (TAM) since macrophages have been implicated as key players in both the pharmacology of carriermediated therapies [10, 37] and in cancer progression [21, 43] . To test this hypothesis, we first sought to identify the cells within tumor tissue that engulf systemically administered PLN. We found that there was significant internalization of PLN by TAM and CD11b + Gr1 + myeloid progenitor cells (P = 0.029) but not by tumor-infiltrating lymphocytes ( Fig. 2A-C) or non-leukocytes (data not shown), suggesting that macrophages mediating protumoral effects of PLN. To verify this, we next conducted tumor growth studies in MaFIA mice treated with PLN or vehicle control, with and without in vivo macrophage depletion. We found that depletion of macrophages abrogated PLN-induced tumor growth ( Fig. 2D ; P < 0.0001), indicating that they are the primary mediators of the protumoral effects of the carrier.
PLN-alendronate mitigates carrier-induced splenic myeloid cell infiltration and polarization
Given that PLNs are increasingly used as carriers for targeted therapies and immunotherapies, we aimed to determine whether the tumor promoting effects of the carrier can be reversed with an immune modulatory and non-cytotoxic drug cargo. Since alendronate inhibits the activity of osteoclasts, a specialized population of bone macrophages and has been found to have antitumor activity through its effects on T-cells [55] , we theorize that formulating PLN with alendronate will mitigate the immunosuppressive effects of the carrier that are mediated by macrophages. To test this strategy, we treated tumorbearing mice with PLN-alen, PLN, or vehicle control and determined the impact on splenocytes. We chose to inspect splenocytes (consisting of myeloid and lymphoid immune cells including macrophages, MDSCs, and T cells), because the spleen is a secondary lymphoid organ and this collection of splenic cells plays an important role in the immune response to cancer [7] . Paradoxically, the spleen may even serve as site that helps orchestrate tumor immune tolerance [16] . We found that PLN significantly increased the splenic population of CD11b + Gr1 + cells as compared to vehicle control (P = 0.021) (Fig. 3A-B ). In contrast, PLN-alen resulted in a reduction of the splenic population of CD11b + Gr1 + cells compared to PLN, and did not result in significant accumulation in comparison to vehicle control (Fig. 3A-B) . Since the splenic CD11b + Gr1 + cell population consists of numerous subpopulations of granulocytic and monocytic cells with the potential to impede T-cell mediated immunity during cancer and infection [35, 53, 54] , we further characterized the splenic CD11b + Gr1 + cell subpopulations in each treatment group. This revealed significant accumulation of granulocytes, consisting of neutrophils, basophils and eosinophils in the PLN treated group (P = 0.034) that was not observed with PLN-alen (Fig. 3C) . Moreover, significant accumulation of both inflammatory and resident monocytes was also observed after PLN treatment (P = 0.021 and P = 0.040, respectively) but not with PLNalen (Fig. 3C) , suggesting that loading alendronate mitigated these effects of the PLN. In addition to these effects on splenic myeloid cell accumulation, we observed that PLN increased expression of arginase-1 in CD11b + Gr + cells as compared to vehicle control (P = 0.032), suggesting immunosuppressive functionality in this population, whereas PLN-alen did not (Fig. 4A) . Moreover, splenic macrophages were predominantly M1-like in control mice while PLN treatment diminished M1-macrophages (P = 0.034) and increased M2-macrophages, and PLN-alen moderately alleviated this effect of the carrier on M2-macrophages (Fig. 4B ).
To further probe the impact of treatment on immune functionality, we assessed T-cell cytokine and perforin production in response to ex vivo stimulation with PMA/ionomycin. We observed that both PLN and PLN-alen diminished overall cytokine production in CD8 + T-cells (Fig. 5) , consistent with an immunomodulatory effect by the PLN carrier and its drug cargo. Interestingly, loading alendronate into PLN resulted in a shift in the profile of multi-cytokine producing T-cells, with increased proportions of IFNγ + perforin + multi-cytokine producing CD8 + T-cells (Supplemental Fig. S4 ), suggesting increased cytolytic potential. Taken together, these immunological changes indicate that the PLN carrier may increase accumulation of myeloid cells with immunosuppressive functionality and globally suppress CD8 + T-cell cytokine production. Loading alendronate into PLN appeared to alleviate the effects of the carrier on myeloid cell accumulation and functional polarization, with moderate potentiation of T-cell IFNγ + perforin + responses.
PLN-alendronate abrogates carrier-induced tumor growth
We next determined the extent to which loading alendronate into PLN would abolish the tumor promoting effects previously reported to be associated with the PLN carrier. We found that PLN significantly accelerated tumor progression compared to vehicle control; the mean tumor volumes at endpoint were 886 mm 3 and 374 mm 3 , respectively (P < 0.0001) (Fig. 6A ) and tumor-free survival was significantly diminished in PLN treated mice (P = 0.0046) (Fig. 6B) . Importantly PLNalen not only abolished this effect but also appeared to have moderate antitumor effects with mean tumor volume in PLN-alen treated mice of 289 mm 3 ( Fig. 6A ) and significantly longer tumor-free survival compared to vehicle treated mice (P = 0.028) (Fig. 6B ). This appeared to require carrier-mediated delivery of alendronate since co-administration of PLN with conventional "free" alendronate only minimally diminished the tumor-promoting potential of the lipid carrier (Fig. 6A) .
PLN-alen diminished carrier-induced tumor immunosuppression
We examined the tumor-associated leukocyte populations since prior reports suggest that PLN may alter TAM functionality. Similar to + Gr1 + subpopulations that increased were inflammatory monocytes and granulocytes, but an increase in resident monocytes was also observed. Total n = 11; data are mean + SEM (rank-transformed data in Supplemental Tables S4-S9) ; one-way analysis of variance based on ranks; n.s., not significant. previously published findings [56] , we also observed that PLN increased the number of TAMs, and this effect was prevented by PLNalen, although these findings did not reach statistical significance probably due to the small sample size (Supplemental Fig. S5 ). To determine the impact on activation and polarization of TAMs, expression of iNOS (typical of classically activated inflammatory M1 macrophages) and Arg1 (typical of alternatively-activated anti-inflammatory M2 macrophages) [24, 34] , were assessed by flow cytometry. We found that PLN, but not PLN-alen, increased numbers of a mixed M1/M2 TAM population, characterized by production of both iNOS and Arg1, as compared to vehicle control (P = 0.045) (Fig. 7A) . In addition to TAMs, CD11b + Gr1 + myeloid cells have also been shown to play a role in promoting cancer progression. While not statistically significant, we observed that PLN increased Arg1 expression in MDSC, whereas PLNalen diminished this effect of the carrier (Fig. 7B) . Together, these results indicate that PLN enhances immunosuppressive potential of myeloid cells in the tumor microenvironment and suggest that encapsulating alendronate counteracts these effects. Further, tumor gene expression analysis of M1 macrophage marker (iNOS) and cytokines (TNFα and IFNγ) supports these flow cytometry data (Supplemental Fig. S6 ). Vehicle-treated and PLN-treated mice had low tumor-associated expression of iNOS suggesting a tolerogenic TAM profile. However, co-administration of alendronate, either free or encapsulated, along with PLN resulted in elevated expression of iNOS within the tumor. These data suggest that alendronate may induce skewing of the TAM phenotype from M2 to M1 or mixed M1/M2 phenotypes. In addition, PLN suppressed IFNγ and TNFα gene expression in tumors, consistent with previously published findings supporting an immunosuppressed state.
Discussion
Drug delivery using nanoparticle carriers drastically alters the pharmacokinetics and pharmacodynamics of the drug cargo as compared to the conventional non-carrier mediated formulation due to changes in tissue and cellular distribution dictated by the carrier [9] . This has been exploited to improve drug pharmacokinetic parameters (e.g., half-life, clearance, systemic exposure), enable passive tumor targeting through the EPR effect and active targeting through functionalization with targeting moieties such as antibodies, and to considerably improve tolerability by limiting normal tissue exposure. However, carrier-mediated formulations also significantly increase interactions with the immune system and these interactions have the potential to lead to detrimental effects [36, 61] .
In patients, the acute infusion reactions associated with administration of liposomal drugs has been linked to carrier-induced complement activation [12, 66] and production of complement anaphylotoxins C3a, C4a, and C5a [65] . Nanoparticles are also internalized by cells of the MPS such as hepatic Kupffer cells and splenic macrophages [27, 73] . This interaction with the MPS may have important clinical significance as low MPS function or cell count has been shown to correlate with decreased nanoparticle clearance in patients and in several preclinical animal models [10, 37] . Although carrier interactions with the immune system have been shown to affect drug pharmacokinetics and toxicity, their impact on the anticancer efficacy of the carrier-mediated drug is unclear. Macrophages play a central role in clearance of nanoparticles from the circulation but the impact of the nanoparticles on the functionality of macrophages remains to be fully elucidated.
Our findings reveal that macrophages mediate the protumoral effects of PLN through immunosuppressive mechanisms as indicated by polarization of tumor macrophages towards a mixed M1/M2-phenotype and increased arginase-expressing immature myeloid-derived cells. Mechanistically, PLNs that are phagocytosed by myeloid cells may activate an anti-inflammatory program much like that associated with uptake of apoptotic cells [2, 17] that would spur TGFβ production by macrophages. In fact, uptake of liposomes by peritoneal macrophage can induce a tolerogenic M2-like phenotype [15] . The production of TGFβ by these tolerogenic myeloid cells can lead to secondary release of CeC motif chemokine ligand 2 (CCL2, also known as monocyte chemotactic protein 1 [MCP-1]) and emigration of immature myeloid cells from the bone marrow into circulation and organs of the MPS such as spleen [60, 76] (Fig. 8) . Consistent with this hypothesis, we found increased splenic infiltration of immature myeloid cell populations such as inflammatory monocytes that have the potential to differentiate into both M1 and M2 macrophages [5, 22] . Based on the inflammatory state of an organ, immature myeloid cells may then take on anti-inflammatory properties associated with M2 activation that impair T-cell mediated immunity [68] , increase neoangiogenesis [31, 74] , and spur tumor growth (Fig. 8) . Indeed, our results show that PLN treatment was associated with global suppression of cytokine production in tumor infiltrating T-cells. Moreover, recent evidence in patients with ovarian cancer showed that circulating monocyte numbers and plasma CCL2 levels correlated with PLD clearance [37] and plasma PLD levels [63] , respectively. In addition, CCL2 knockout mice bearing ovarian tumor xenografts were found to have altered clearance of PLD as compared to control mice [62, 63] . These data further support a link between PLN uptake by myeloid cells of the monocyte-macrophage lineage and their immune functionality.
The extent to which our findings are broadly applicable to other nanoparticles remains to be determined. There is substantial heterogeneity in physical (e.g., size, shape, charge) and chemical (e.g., composition) properties among different types of nanomedicines, and these physicochemical parameters are known to affect their in vivo pharmacokinetics and pharmacodynamics. Hence, it should not be assumed that our observations will be generalizable beyond the PLN that we tested. Further studies are also warranted to identify the PLN component that is responsible for immunomodulation and elucidate the precise molecular mechanisms. There is strong evidence in the literature for PEG as an agent in reducing immunogenicity and as an immunosuppressive-camouflage agent [14, 70] . In cancer drug delivery, PEG-lipid nanoemulsions (mean particle size 125 nm) induced immunologic tolerance that was mediated by macrophages [71] . In protein therapeutics, PEG suppressed antibody responses against conjugated antigens thereby inducing a tolerogenic state [58] and this approach has been utilized to optimize pharmacokinetics of therapeutic proteins (e.g. PEG-asparaginase) [11] . In organ transplantation, the addition of PEG to organ preservation solutions significantly improved organ function and decreased inflammation and fibrosis through suppression of the host immune responses against the transplanted organ [28, 67] . The immune modulatory effects of PEG are increasingly recognized, and the use of PEG in cancer drug delivery has become a controversy [69] that is unlikely to be resolved until the precise mechanisms, and its impact on anticancer efficacy of the payload drug, are clarified.
Even if PEG is the moiety responsible for immunosuppression, it may not be possible to forgo the use of PEG in all nanomedicines. Pegylation has been a successful strategy to prolong the circulating halflife of liposome-delivered drugs and this has directly correlated with enhanced tumor drug accumulation. Moreover, given that there are several PLN-drugs already approved for use in patients, it would be imperative to identify strategies to mitigate the undesired immunosuppression induced by the PLN carrier [1, 47] . Importantly, we demonstrated here that PLN-alen, but not free alendronate, mitigated the tumor-promoting effects of the PLN carrier. Encapsulating alendronate into PLN reversed carrier-associated effects on myeloid cell functionality and accumulation in tumor and spleen. Given that PLNalen hardly interacts with tumor cells in vitro and has not been found to have direct cytotoxicity on numerous tumorigenic cell lines (IC 50 values > 50 μM, unpublished data from the Gabizon laboratory and from the National Cancer Institute's Nanotechnology Characterization Laboratory), the observed inhibition of tumor growth is likely due to the immune modulatory effects of PLN-alen.
Aminobisphosphonates, such as alendronate, are potent inhibitors of the mevalonate pathway which is being targeted as a strategy to promote immunogenic destruction of cancer cells [55] . Aminobisphosphonates have been shown to have immune stimulatory effects such as induction of proinflammatory cytokines, sensitization of macrophages to inflammatory stimuli, and activation of gamma-delta T-cells [57] . In contrast, non-aminobisphosphonates such as clodronate, primarily act via production of toxic ATP analogues and have been shown to inhibit production of inflammatory mediators and cause overall macrophage suppression and toxicity [18, 57] . Encapsulation of alendronate into liposomes is likely to modify the immune modulatory effects of the drug, as the carrier will dictate the pharmacokinetic profile and may drastically alter cellular and molecular interactions. The fact that PLN-alen potentiated IFNγ + perforin + responses in multi-cytokine producing Tcells (Supplemental Fig. S4 ) suggests increased T-cell cytolytic potential that may partially explain the moderate antitumor activity we observed with PLN-alen treatment. It is likely that there are additional immunomodulatory effects of PLN-alen on other cell types such as gamma-delta T-cells [51] that will need to be fully elucidated and may be relevant particularly in humans. Together, these data suggest the coencapsulation of aminobisphosphonates with other immunotherapies or chemotherapies as one possible strategy to significantly enhance the anticancer efficacy of liposome-mediated drugs. This approach is strongly supported by a recent report by Shmeeda et al. that co-encapsulating alendronate with doxorubicin in a PLN resulted in synergistic anticancer activity in an immunocompetent mouse model of cancer [59] . Interestingly, there was no synergy observed in an immunodeficient tumor model [59] , which is consistent with the immunomodulatory mechanisms of action of alendronate that we and others [51] have observed. The extent to which our findings are generalizable to other types of tumors remains to be determined. While we observed in the TC-1 tumor model that the impact of PLN and PLN-alen was greatest for mixed M1/ M2 TAMs, others have reported that liposomal aminobisphosphonates increased M1 polarization of J774 murine macrophages when co-cultured with 4T1 breast cancer cells ( [64] . There are several factors that may explain these disparate observations including differences in tumor biology, differences in functionality of primary TAMs versus immortal macrophage cell lines, and differences between in vitro versus in vivo exposure to liposomes. Given that there is significant heterogeneity in tumor immunogenicity and response to therapeutic interventions between different types of malignancies, additional studies are warranted to identify the tumor parameters that determine responses to nanomedicines and to delineate the mechanisms involved.
Our findings challenge the current dogma that PLNs are inert drug carriers, and we theorize that the immunosuppressive properties of PLN have previously been overlooked for several reasons. First, the doses of PLN anticancer drugs used in animal models is typically much larger than that used in patients, which may allow the drug cargo effects to override the immunosuppressive effect of the carrier. This may explain why nanomedicines clearly outperform the free drug comparator in preclinical studies while the differences are very small in clinical trials. In addition, preclinical drug development strategies have historically focused on antiproliferative effects of the drug payload, and not on evaluating immune modulatory or protumoral effects of the PLN carrier. Hence, tumor models were selected that are highly sensitive to cytotoxic effects of PLN-drugs, but these models were not sensitive to protumoral effects and their immune-responsiveness is not well characterized. Moreover, the desire to evaluate tumoricidal effects in human cancer cells also led to the prevalent use of immune deficient mouse models that likely contributed to the masking of immunosuppressive effects of PLNs. Even among the immunocompetent mouse models, there are major differences in global immune status (e.g., balance of Th1-Th2 cytokines or M1-M2 macrophages) [72] that affect nanoparticle disposition. The Th1-dominant strains such as C57BL/6 were reported to have slower rates of clearance of pegylated 300-nm cylindrical hydrogel nanoparticles than the Th2-dominant strains such as BALB/c [33] . These differences in clearance were correlated with M1 macrophage polarization and lower particle uptake in Th1 strains, and M2 macrophage polarization and higher nanoparticle uptake in the Th2 strains. Likewise, when silica nanoparticles were tested in vitro with THP1 cells, an immortalized human monocytic cell line, alternatively activated (M2-like) THP1 cells demonstrated higher nanoparticle uptake than classically activated (M1-like) THP1 cells [29] .
We believe that the dearth of in vivo and long-term immunological studies during the preclinical development of nanoparticle drugs [30] contributed to missing the immunosuppressive properties of some nanoparticles such as PLN. The preclinical evaluation of the immunological effects of nanoparticles have historically relied on in vitro studies and short-term studies in animal models which are best suited for evaluating acute effects such as induction of blood complement activation and cytokine release syndromes. Whereas, immunosuppressive effects, especially those that affect the adaptive immune system, tend to manifest after longer periods and require more complex in vivo immunological assessments such as the ones that we conducted in this study. Given the pivotal roles of the immune system in both cancer progression and regression, we propose that immuneresponsive tumor models and in-depth immune functional studies should be incorporated in the current preclinical drug development paradigm for cancer nanomedicines.
Conclusion
Liposomes will likely continue to be heavily utilized for cancer drug delivery since they have been the most successful clinically and are proven to improve drug tolerability in cancer patients. While nanoparticle drug delivery has the potential to also significantly improve anticancer efficacy, these expectations remain to be broadly realized in the clinic for the treatment of solid tumors. We have begun to identify some of the barriers to clinical translation and unravel the mechanisms of interactions between PLNs and the immune system. We anticipate that this work will lay the foundation for the development of new preclinical models with increased clinical relevance and new therapeutic approaches targeting macrophage functional polarization to enhance the anticancer efficacy of PLN drugs. Importantly, we show that PLN-alendronate can reverse the effects of the PLN carrier on macrophages, supporting combination therapy with liposomal alendronate as a rapidly translatable strategy to increase the anticancer efficacy of liposomal drugs since alendronate is already approved for treatment of osteoporosis. As with traditional cytotoxic chemotherapy, the next generation of immunotherapies will also likely strive to exploit nanoparticle drug delivery as a strategy to increase tumor specificity and improve pharmacokinetic parameters. It is therefore imperative that the complex interactions between the drug cargo, carrier, and tumor immunologic milieu are well understood and utilized to achieve the full anticancer potential of carrier-mediated therapies [4] .
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